ライフサイエンスコーパス: modifier

1 A) has been proposed as a type of epigenomic modifier.

2 ymer when changing from a basic to an acidic modifier.

3 detection and it reached 30 pg g(-1) with Ir modifier.

4 T (fragile histidine triad) as a novel BMPR2 modifier.

5 aphite furnace together with Pd/Mg(NO(3))(2) modifier.

6 e NKX2-5 variant's contribution as a genetic modifier.

7 causes CTDs, thus implicating this gene as a modifier.

8 g because of its role as a global epigenetic modifier.

9 protein 1 (ROM1) could serve as a phenotypic modifier.

10 esented herein with the use of a water vapor modifier.

11 o loss-of-function alterations of epigenetic modifiers.

12 y result from upregulation of key epigenetic modifiers.

13 ospho-sulpho switch driven by small molecule modifiers.

14 anscriptome, and was enriched for epigenetic modifiers.

15 -7 and MMP9 as possible extracellular matrix modifiers.

16 e genes that led to the identification of 60 modifiers.

17 onally poisoning certain MNPs using suitable modifiers.

18 n data to identify clinically relevant BMPR2 modifiers.

19 ent therapeutics and SMN-independent disease modifiers.

20 ing cilium, pre-mRNA splicing and epigenetic modifiers.

21 (PTCLs) are uniquely sensitive to epigenetic modifiers.

22 ith focus on different nano-scaled electrode modifiers.

23 encoding transcription factors and chromatin modifiers.

24 odels with alternative causes or with effect modifiers.

25 x-dCas9(3.7) fused to one of five epigenetic modifiers.

26 n family is a well-known group of epigenetic modifiers.

27 r, and frailty were evaluated as association modifiers.

28 n to social factors as confounders or effect modifiers.

29 ould be manipulated by design of the organic modifiers.

30 Ubiquitin fold modifier 1 (UFM1) is a small, metazoan-specific, ubiquit

31 olutes(6,7) and the effects of single growth modifiers(8,9).

32 We tested for diabetes as an effect modifier, adjusting for potential confounders such as sm

33 Chromatin modifiers affect spatiotemporal gene expression programs

34 f CaWss1 with Cdc48 and small ubiquitin-like modifier, although not strictly required, contribute to

35 Genetic modifier analysis among cases with APOL1 risk genotypes

36 ZPR1 represents a protective modifier and a therapeutic target for developing a new m

37 with high water concentration in the alcohol modifier and carbon dioxide.

38 ciprocal regulatory module between chromatin modifiers and circadian clock oscillators orchestrates d

39 tational modeling to characterize additional modifiers and input pathways.

40 A critical role of epigenetic modifiers and their specific chromatin modifications has

41 is crucial for experimental data on disease modifiers and their translation to clinical trials and t

42 dynamics with expression regulation of m(6)A modifiers and uncover a selective and critical role of A

43 We found that SUMO (Small Ubiquitin-like Modifier) and SUMO ligase Ubc9 are required for efficien

44 PD gene target agents (such as GBA or LRRK2 modifiers) and other potential disease modifying drugs p

45 ctionality, checkpoint regulators, chromatin modifiers, and copy-number alterations in mediating sele

46 lt to identify unique allelic variants, gene modifiers, and epigenetic factors that strongly affect t

47 matching among different MNPs, corresponding modifiers, and porous nanomaterials makes our strategy p

48 First, Hox genes function as activators, modifiers, and suppressors of trh expression, which in t

49 antify the contribution of genotype, genetic modifiers, and XCI to phenotypic severity.

50 Finally, using Feldman and Liberman's modifier approach, we investigate the conditions under w

51 genetic interactions associated with complex modifier architectures, our analysis also highlights the

52 e underlying mechanisms by which these m(6)A modifiers are regulated remain elusive.

53 ilable small molecule inhibitors for histone modifiers as tool compounds to study the functional sign

54 segregation pattern consistent with a single modifier associated with conditional essentiality.

55 molecular, and cellular investigation of the modifiers at this locus.

56 t modify SVAS offers the potential for novel modifier-based therapeutics.

57 ng a strong replication origin and chromatin modifier binding sites capable of shifting a targeted mi

58 RC Harwell Institute lacks the chromosome 11 modifier but instead harbors an ~37 Mb region containing

59 glucose metabolism disorders as a potential modifier by comparing associations between participants

60 to the TH promoter recruited the epigenetic modifier cAMP-response element-binding protein-binding p

61 re, separations of isomeric analytes using a modifier can be related to the thermochemistry of the cl

62 impairment of the functions of these histone modifiers can lead to dysregulation of lipogenesis and t

63 In animal models, treatment with epigenetic modifiers can mitigate the effects of sepsis and improve

64 Gene expression of modifier candidates and DNA methylation on chromosome 5

65 Human SNP variants of several modifier candidates were depleted in colorectal cancer g

66 that AMD is an effective hERG channel-gating modifier capable of lengthening the plateau phase of car

67 Identifying genetic modifiers capable of altering the course of muscular dys

68 m(6)A modifiers catalyze this reversible modification.

69 Here we describe chemical epigenetic modifiers (CEMs) designed to activate the expression of

70 tion of the injury site extracellular matrix modifier chondroitinase ABC (chABC), tested here in glia

71 IUGR lambs treated with adrenergic receptor modifiers: clenbuterol atenolol and SR59230A (IUGR-AR).

72 tained even using polar additives in alcohol modifier/CO(2) based eluents.

73 rapid depletion of the dCas9-fused epigenome modifier complex from the target site and enables tempor

74 substrates of the SUMO (small ubiquitin-like modifier) conjugation pathway.

75 structural materials, biomaterials, rheology modifiers, construction, paper enhancement, and others.

76 A gradient from 2 to 40% methanol modifier containing 0.1% TFA as an acidic additive was a

77 Modern humans are instead niche modifiers, continually changing their environments irres

78 This work highlights a possible genetic modifier contributing to pancreatic agenesis and demonst

79 These homologs are termed cytokine response modifier (Crm) proteins, containing a TNF-binding domain

80 For instance, cytokine response modifier D (CrmD) inhibits mouse and human TNF and mouse

81 , interact with and recruit specific histone modifiers, directing specificity toward lipogenesis.

82 rogens, functional monomers, organic surface modifiers, dummy templates, and cross-linkers.

83 ted STAT (PIAS) 1, a small ubiquitin-related modifier E3 ligase that facilitates C/EBPbeta degradatio

84 al repeat alleles of 10 genes had a possible modifier effect in AO in Portuguese TTR-FAP Val30Met fam

85 us, in HD, it is uncertain whether the RRM2B modifier effect on timing of onset may be due to a DNA i

86 In contrast, the FAN1 modifier effects reveal that functional FAN1 acts to sup

87 istently, among 13 drugs targeting chromatin modifiers, EHMT2 inhibitors were highly effective in red

88 Multi-walled carbon nanotubes in the modifier enhance conductivity and facilitate the electro

89 Here, we show that the ubiquitin-like modifier FAT10 regulates OTUB1 stability and functionali

90 s with the cytokine-inducible ubiquitin-like modifier FAT10, which gets covalently conjugated to hund

91 cohort assessed, TMEM106B acts as a genetic modifier for cognitive trajectory in PD.

92 therefore, be considered as potential effect modifiers for KSHV-associated cancers in sub-Saharan Afr

93 neurological diseases, found also to act as modifiers for other disorders.

94 Epigenetic modifiers frequently harbor loss-of-function mutations i

95 lh1, the ortholog of a third HD age-at-onset modifier gene (MLH1), which suppresses somatic expansion

96 at glial cell-specific loss of the chromatin modifier gene dATRX in the subperineurial glial layer le

97 after 1985 and recruited into the French CF Modifier Gene Study since 2004.

98 in terms of identification of new causative/modifier genes and polygenic conditions.

99 orphisms were sequenced in candidate genetic modifier genes encoding known RPGR-interacting proteins.

100 rent knowledge of the genetics and candidate modifier genes in PXE, a multifactorial disease at the g

101 Top mutant huntingtin toxicity modifier genes included several Nme genes and several ge

102 specific enzyme, we distinguish a subset of modifier genes serving as buffers or potentiators of var

103 o identify and pharmaceutically target BMPR2 modifier genes to improve PAH.

104 d the mouse orthologs of two HD age-at-onset modifier genes, FAN1 and RRM2B, for an influence on soma

105 recurrent somatic alterations in epigenetic modifier genes.

106 heimer's disease is highly variable, and its modifiers (genetic or environmental) could act through e

107 Our studies therefore reveal how a chromatin modifier governs cellular responses during infection.

108 thermore, the impact of genotype and genetic modifiers has been demonstrated in affected males but ha

109 r understanding the disease process, genetic modifiers have been disclosed that explain the phenotypi

110 riol enhanced the recruitment of the histone modifier HDAC1 at the Il9 gene promoter.

111 ond their well-characterized role as histone modifiers, HDACs also interact with several nonhistone s

112 s regulated by the expression of a chromatin modifier, histone deacetylase 11 (HDAC11).

113 gulatory processes, including DNA or histone modifiers, histone readers, and chromatin regulatory pro

114 ntaining 28 (TRIM28), which is an epigenetic modifier implicated in gene transcription and cell diffe

115 mary grains and an effective secondary phase modifier in AA7075.

116 sive complex 2 (PRC2) is a crucial chromatin modifier in executing neurodevelopmental programs.

117 ochondrial retrograde signaling as a disease modifier in primary antibody deficiency.

118 24) showed recurrent mutations of epigenetic modifiers in 74% of cases, involving notably KMT2C (26%)

119 n, and metabolism, yet the roles of specific modifiers in different cancer types are not well defined

120 among the most highly inactivated epigenetic modifiers in lung cancer.

121 ies and for a search for ciliopathy genes as modifiers in other human conditions with forebrain defec

122 tually in association with biologic response modifiers in the early phases, whereas in patients with

123 odifiers provides guidance on the pairing of modifiers in the synthesis of crystalline materials.

124 we determined the functional roles of BMPR2 modifiers in vitro and tested the repurposed drug enzast

125 interactions involving 191 distinct genetic modifiers, including 38 that are synthetic sick/lethal a

126 d transcription regulators such as chromatin modifiers, including a significant number of highly cons

127 these small but versatile protein and lipid modifiers interact with a plethora of proteins, which ei

128 results highlight the complexity of crystal-modifier interactions mediated by the structure and dyna

129 Synergism between two crystal growth modifiers is expected, but the antagonistic cooperativit

130 The activity of histone modifiers is influenced by their ability to sense modifi

131 Identifying disease modifiers is of considerable translational interest, as

132 Maintenance of epigenetic modifiers is of utmost importance to preserve the epigen

133 Identifying recombination rate modifiers is thus of both fundamental and practical inte

134 The ubiquitin-like modifier ISG15 (interferon-stimulated gene 15) is induce

135 ng, among others, the ubiquitin-like protein modifier ISG15 and the ubiquitin specific peptidase USP1

136 (ISG-15), also known as ISG15 ubiquitin like modifier (ISG15), was observed early, with a progressive

137 e identified in genes encoding the chromatin modifier KAT6A, and CTNNA1, encoding catenin alpha-1.

138 hanistically, ZNF750 recruits the epigenetic modifiers KDM1A and HDAC1 to the promoter regions of LAM

139 ll lymphoma via degradation of the chromatin modifier KMT2D.

140 view the major pathways and dominant genetic modifiers known to be relevant players in human NAFLD an

141 Multiple dosage-dependent modifier loci on PWD chromosome 5 each contributed to tu

142 nd the like), rather than the smaller effect modifier loci that more subtly influence colour.

143 s essential for the degradation of chromatin modifier lymphoid-specific helicase (LSH) by counteracti

144 an be caused by variation in two independent modifiers, MET1 and OPT1, each with roles associated wit

145 categories: Surfactants modifiers, polymeric modifiers, metallic nanomaterials, carbon based nano-mod

146 ), cytokines (IL23A, IL19, and IL1B), matrix modifiers (MMP12 and SPARCL1), immune regulators (IDO1,

147 lity protein maize (QPM) by introgressing o2 modifiers (Mo2s) into the o2 mutant benefits millions of

148 mixture and without the need of enantiopure modifier molecules.

149 lele of oy1 (Oy1-N1989) and a cis-regulatory modifier named very oil yellow1 (vey1) that varies betwe

150 B kinase (IKK) complex, NF-kappaB essential modifier (NEMO), and IKKbeta.

151 and are frequently targeted by deadly gating-modifier neurotoxins, including tarantula toxins, which

152 and female human participants heard simple (modifier-noun) English phrases that varied in the degree

153 p with the discovery of a selective covalent modifier of adenosine deaminase (ADA).

154 IFNG variant rs2069705 seems to be a genetic modifier of clinical outcome of Leishmania infection; in

155 We mapped a genetic modifier of crossover frequency in Col x Bur populations

156 e identify Bsnd (alias Barttin) as a genetic modifier of cystic kidney disease in Joubert syndrome, u

157 t within the SVA insertion acts as a genetic modifier of disease expressivity in XDP.

158 bral disease in cALD and suggest it may be a modifier of disease.

159 ry aspect of an ecosystem, and is a critical modifier of ecosystem responses to global change.

160 the identification of muscleblind as a novel modifier of FUS-mediated neurodegeneration in vivo.

161 results establish Sox9 as a dosage-sensitive modifier of Jag1(+/-) liver phenotypes with a permissive

162 onfirms Dot1l to be a genetic and epigenetic modifier of kidney fibrosis, reveals a new mechanism reg

163 uggest the existence of a cell type-specific modifier of MNV entry.IMPORTANCE MNV is a prevalent mode

164 in A6 was previously identified as a genetic modifier of muscle injury and disease.

165 Sex is a key modifier of neurological disease outcomes.

166 A key modifier of outcomes is access to healthcare.

167 ings identify an orphan receptor as a potent modifier of short-term memory and supplement classical P

168 ibrosis biology and may be a novel potential modifier of SSc fibroblast biology.

169 the application of Oxr1 as a viable and safe modifier of TDP-43-associated ALS phenotypes.

170 We found that gender is a significant effect modifier of thalamic GABA/Water's relationship with AQ a

171 y also suggest that GATA6 may be a potential modifier of the cardiac pacemaker.

172 Occlusion site was a strong modifier of the effect of bridging therapy on outcome (p

173 nvestigate the conditions under which a rare modifier of the extent of conformity or the number of ro

174 amine-expanded ataxin-3 is a concomitant and modifier of the molecular pathogenesis of Machado-Joseph

175 ta suggest that COVID-19 may be an important modifier of the onset, characteristics and outcome of ac

176 We also learned that FMO3 is an essential modifier of the polyketide.

177 Sex was the most important modifier of the relationship between ACR and PCR, with m

178 , diabetes was a significant positive effect modifier of the relationship between sleep and severe pe

179 Whether or not BMI is a modifier of this pathway needs to be investigated furthe

180 These findings identify torsinB as a potent modifier of torsinA LOF phenotypes and suggest that augm

181 lation at the Ser57 position as an important modifier of ubiquitin function, particularly in response

182 indings establish Sox17 as a tissue-specific modifier of Wnt responses and point to a novel paradigm

183 s study was to analyze whether ATIs are also modifiers of allergic inflammation.

184 nts with SCD, as well as for potential novel modifiers of anemia severity.

185 ciated microbiomes are emerging as important modifiers of brain activity and behavior.

186 rriers in the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA; N = 31 448).

187 We first identified 135 candidate genetic modifiers of C9ALS using whole-genome sequencing (WGS) o

188 int to hypoxia/energy depletion as potential modifiers of CA4P response.

189 We functionally localized modifiers of cAMP signaling, the photo-activated adenyly

190 indicate the existence of cell type-specific modifiers of CD300LF-dependent MNV entry.

191 ed repressors of retrovirus (RV) activity as modifiers of CHMP2BIntron5 toxicity.

192 drug library was performed to identify novel modifiers of cholangiocyte injury in the zebrafish exper

193 ntext and function of these three epigenetic modifiers of chromatin can orchestrate transcriptional d

194 Our results identify novel modifiers of different aspects of HD pathogenesis in med

195 advances this approach for mining druggable modifiers of disease-associated proteins, while cautioni

196 Identifying modifiers of dosage-sensitive genes involved in neurodeg

197 Zebrafish were exposed to selective modifiers of estrogen signaling at larval and adult stag

198 ing dynein light chain) and hook, as genetic modifiers of FTD3-associated mutant CHMP2B toxicity and

199 a 7-d post-injury survival curve to identify modifiers of injury.

200 biased CRISPR-Cas9 screen identified genetic modifiers of lipid droplet formation; surprisingly, vari

201 e used an intercross strategy in mice to map modifiers of muscular dystrophy.

202 ns reported here represent likely drivers or modifiers of myeloproliferative disease.

203 ine variants of the APOE gene are major risk modifiers of neurodegenerative and atherosclerotic disea

204 be used for the identification of allosteric modifiers of olfactory-driven behaviors capable of provi

205 nes involved in DNA maintenance processes as modifiers of onset, including multiple genome-wide signi

206 ic screen, we identified a number of genetic modifiers of poly(GR) toxicity.

207 tissue targeted genetic screen for germline modifiers of polyglutamine aggregation in muscle cells.

208 udies have identified DNA repair pathways as modifiers of somatic instability and disease course in H

209 have received little attention as potential modifiers of the ANPP-CO(2) response.

210 uts to chromatin via cellular metabolism are modifiers of the epigenome.

211 Those genes include epigenetic modifiers of the ESC/E(Z) complex, an effector of respon

212 evasion strategy, and thus may act as effect modifiers of the HSV1-AD association.

213 biota variation to a similar extent as other modifiers of the infant microbiome, such as birth mode.

214 fundamental influences of sex and gender as modifiers of the major causes of death and morbidity.

215 the role of T cells as critical drivers and modifiers of the pathogenesis of atherosclerosis.

216 gene interactions, will prove to be stronger modifiers of the risk for nephropathy.

217 ionally, several heritable and non-heritable modifiers of this effect were identified.

218 etrance, suggesting genetic or environmental modifiers of this episodic disorder, was evident in the

219 his genome-wide screen detected many nuclear modifiers of this ratio and identified one as the cataly

220 unctional system to model the mechanisms and modifiers of tumor evolution.

221 However, inhibition of histone lysine modifiers often leads to local rather than total changes

222 none of these covariates are effect-measure modifiers on the absolute scale, however, the marginal r

223 trate that the SUMO (Small Ubiquitin-related Modifier) pathway crosstalks with the ubiquitin-proteaso

224 The electrode modifier, PDA-Au, provided a functionalizable interface

225 Huwentoxin-IV (HwTx-IV) is a gating modifier peptide toxin from spiders that has weak affini

226 Chromatin modifiers play critical roles in epidermal development,

227 s engaged in several categories: Surfactants modifiers, polymeric modifiers, metallic nanomaterials,

228 The chromatin modifier PRMT7 is the only Type III PRMT found in higher

229 Inflammation is likely a critical disease modifier, promoting susceptibility to depression.

230 Mutations in chromatin modifiers-proteins that shape the epigenomic landscape t

231 int on cooperativity between crystallization modifiers provides guidance on the pairing of modifiers

232 otential and the relocalization of chromatin modifiers (RCM), we hypothesize that increased CpG densi

233 did not alter the activity, while amino acid modifiers reduced enzyme activity.

234 s, metallic nanomaterials, carbon based nano-modifiers (reduced graphene oxide, multi-walled carbon n

235 We notice that the most potent modifiers refer to the glycolysis pathway and that, more

236 By studying chromatin modifiers regulated by epithelial growth factor, we iden

237 ary, we show that cross talk between histone modifiers regulates miR156 and alters hormonal response

238 ns between the fibrotic components and their modifiers remain largely unclear.

239 4, 33, and 29 ng g(-1) for Ir, Ru, and Pd/Mg modifiers, respectively.

240 uronal excitability, we performed an in vivo modifier screen of the NCKX(zydeco) seizure phenotype.

241 RNA-Seq/ChIP-Seq and a subsequent modifier screen reveal that pdm3 represses expression of

242 In addition, genetic modifier screens can be used to elucidate disease mechan

243 arginine (PR), and are protective in genetic modifier screens.

244 y disease, diabetes, and so on), and disease modifiers (sex, genes, others) contribute to the develop

245 onal evidence that a frequent onset-delaying modifier signal does not alter FAN1 coding sequence but

246 We also idenified a third onset-hastening modifier signal whose mechanism of action remains uncert

247 ccounting for two infrequent onset-hastening modifier signals.

248 nscription factors, cofactors, and chromatin modifiers spatially segregates TAD regions into various

249 ent clinical contexts, and the evaluation of modifiers such as genetic ancestry, has not been perform

250 transcription factors, repressive chromatin-modifiers such as PRC2 and DNA methyl-transferases, and

251 NA-dependent ATPase UAP56/DDX39B and histone modifiers such as the SIN3 deacetylase in humans.

252 This has prompted the development of Hb modifiers, such as aromatic aldehydes, with the intent o

253 regulation of all steps of HR by the protein modifier SUMO, which has been increasingly recognized fo

254 of the isoforms of the small ubiquitin-like modifier (SUMO) affects thousands of proteins in the hum

255 ia interactions between small ubiquitin-like modifier (SUMO) and SUMO interaction motif (SIM), and th

256 disassembly, including small ubiquitin-like modifier (SUMO) conjugating enzymes.

257 identified, such as the small ubiquitin-like modifier (SUMO) domain, phospholipase A2 and PrsW-family

258 Small ubiquitin-like modifier (SUMO) is a peptide that can be post-translatio

259 Conjugation to the small ubiquitin-like modifier (SUMO) is emerging as an important mechanism to

260 Dynamic small ubiquitin-like modifier (SUMO) linkages to diverse cellular protein gro

261 covalent attachment of small ubiquitin-like modifier (SUMO) proteins to a lysine (Lys) residue on ta

262 by the attachment of small ubiquitin-related modifier (SUMO) proteins to lysine side chains to produc

263 clear antigen (PCNA), a small ubiquitin-like modifier (SUMO)-targeted substrate, and thus differs fro

264 ubiquitin-like protein small ubiquitin-like modifier (SUMO).

265 roteins modified by the small ubiquitin-like modifier (SUMO).

266 conjugated to either the small ubiquitinlike modifier SUMO1 or SUMO2, but only SUMO2-conjugated PCNA

267 Small ubiquitin-like modifier (SUMO1-3) conjugation (SUMOylation), a posttran

268 ol to quantify the fraction of an epigenetic modifier that is bound to a pharmacological inhibitor (t

269 l, metazoan-specific, ubiquitin-like protein modifier that is essential for embryonic development.

270 To identify modifiers that act at the level of CAG expansion and/or

271 ters and Boolean searches with operators and modifiers that allow selection of specific cohorts cover

272 We exposed primary cells to disease-related modifiers that alter epithelial morphology, including IL

273 combination of low-dose adjuvant epigenetic modifiers that disrupts this premetastatic microenvironm

274 ion, Yki has been shown to recruit chromatin modifiers that enhance chromatin accessibility and there

275 ation raises the possibility that epigenetic modifiers that impact on the TET-5-hmC pathway may be a

276 ecome evident that genes encoding epigenetic modifiers that locally and globally regulate gene expres

277 To identify chromatin modifiers that sustain tumor growth, we performed an epi

278 and ammonium acetate in water-rich methanol modifier, the ammonium hydroxide in water additive showe

279 dent recruitment of the SetDB1/Wde chromatin modifier to confer repression of genomic parasites.

280 The inclusion of the water vapor modifier to the FAIMS methodology is made more robust wi

281 nucleosome remodeling complexes, and histone modifiers to engage chromatin, thereby initiating the fo

282 ved peak capacity with the addition of vapor modifiers to the carrier gas.

283 As some gating modifier toxins have affinity for model lipid bilayers,

284 yers, a tripartite relationship among gating modifier toxins, voltage-gated ion channels, and the lip

285 variants in each of the major known genetic modifiers (variants in patatin-like phospholipase domain

286 essivity graded by genetic and environmental modifiers, via poorly understood mechanisms.

287 n the degree of semantic constraint that the modifier (W1) exerted on the noun (W2), as in pairs, suc

288 To explain selectivity effects due to the modifier, we have selected a series of positional isomer

289 To further identify disease-relevant genetic modifiers, we applied our screening approach to two mous

290 Genetic modifiers were identified that alter the effect of Ven1(

291 The following modifiers were investigated: water, linear and branched

292 Different chemical modifiers were optimized namely; Ir, Ru, and Pd/Mg nitra

293 an blood pressure effect adjusted for effect modifiers were performed.

294 ld-standard estimates when continuous effect modifiers were represented as categorical variables.

295 nprick pain sensitivity, as potential effect modifiers, were measured using quantitative sensory test

296 mmatory mechanisms of two distinct psoriasis modifiers, which may be directly exploited for therapeut

297 nt (PCI or CABG) and two prespecified effect-modifiers, which were selected on the basis of previous

298 netic interaction with other DNA instability modifiers whose combined effects can hasten or delay ons

299 rning APP stability using a siRNA screen for modifiers whose own reduction diminished APP in human ce

300 nd the binding energy with the corresponding modifier will be different.